Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) made two poster presentations at the American Association for Cancer Research (AACR) annual meeting in Florida this week.
The first poster indicated a PD-L1/CLEVER-1 IHC staining ratio may be used to predict a patient’s response to Faron’s pioneering cancer drug bexmarilimab.
"The finding supports patient selection for planned combination studies with PD-1 blockade refractory patients," said Faron chief executive Markku Jalkanen.
The second poster showed that bexmarilimab can induce activation and help identify cancers.